Hepatitis Monthly

Published by: Kowsar

Effects of Atorvastatin Alongside Conventional Medical Treatment on Liver Fibrosis and Dysfunction in Patients with Chronic Hepatitis B: A Double-Blinded Clinical Trial

Ahmad Hormati 1 , Maryam Jameshorani 2 , Seyed Saeed Sarkeshikian 1 , Mansureh Molaei 1 , Mahdi Jahangiri 1 and Mohammad Reza Ghadir 1 , *
Authors Information
1 Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran
2 Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
Article information
  • Hepatitis Monthly: February 28, 2019, 19 (2); e84656
  • Published Online: February 12, 2019
  • Article Type: Research Article
  • Received: September 26, 2018
  • Revised: December 25, 2018
  • Accepted: February 1, 2019
  • DOI: 10.5812/hepatmon.84656

To Cite: Hormati A, Jameshorani M, Sarkeshikian S S, Molaei M, Jahangiri M , et al. Effects of Atorvastatin Alongside Conventional Medical Treatment on Liver Fibrosis and Dysfunction in Patients with Chronic Hepatitis B: A Double-Blinded Clinical Trial, Hepat Mon. 2019 ; 19(2):e84656. doi: 10.5812/hepatmon.84656.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Ghadir MR, Belbasi M, Heidari A, Jandagh M, Ahmadi I, Habibinejad H, et al. Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. Hepat Mon. 2012;12(2):112-7. doi: 10.5812/hepatmon.822. [PubMed: 22509188]. [PubMed Central: PMC3321318].
  • 2. Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol. 2015;7(22):2404-10. doi: 10.4254/wjh.v7.i22.2404. [PubMed: 26464756]. [PubMed Central: PMC4598611].
  • 3. Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol. 2018;24(31):3488-99. doi: 10.3748/wjg.v24.i31.3488. [PubMed: 30131655]. [PubMed Central: PMC6102499].
  • 4. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of hepatitis B and C in patients with hemophilia: a single-centre descriptive study. Shiraz E-Med J. 2015;16(7). e24573. doi: 10.17795/semj24573.
  • 5. Koohi-Hosseinabadi O, Moini M, Safarpoor A, Derakhshanfar A, Sepehrimanesh M. Effects of dietary Thymus vulgaris extract alone or with atorvastatin on the liver, kidney, heart, and brain histopathological features in diabetic and hyperlipidemic male rats. Comp Clin Path. 2015;24(6):1311-5. doi: 10.1007/s00580-015-2070-7.
  • 6. Huang YW, Lee CL, Yang SS, Fu SC, Chen YY, Wang TC, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B Patients: A nationwide cohort study. Am J Gastroenterol. 2016;111(7):976-85. doi: 10.1038/ajg.2016.179. [PubMed: 27166128].
  • 7. Albert MA, Danielson E, Rifai N, Ridker PM, Prince Investigators . Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA. 2001;286(1):64-70. doi: 10.1001/jama.286.1.64. [PubMed: 11434828].
  • 8. Blake GJ, Ridker PM. Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med. 2000;1(3):161-5. doi: 10.1186/cvm-1-3-161. [PubMed: 11714433]. [PubMed Central: PMC59622].
  • 9. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519-30. doi: 10.2174/138161212799504803. [PubMed: 22364136]. [PubMed Central: PMC3394171].
  • 10. Alizadeh A, Mansour-Ghanaei F, Roozdar A, Joukar F, Sepehrimanesh M, Hojati SA, et al. Laboratory tests, liver vessels color doppler sonography, and fibroscan findings in patients with nonalcoholic fatty liver disease: An observation study. J Clin Imaging Sci. 2018;8:12. doi: 10.4103/jcis.JCIS_93_17. [PubMed: 29692949]. [PubMed Central: PMC5894278].
  • 11. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53(4):702-12. doi: 10.1016/j.jhep.2010.04.025. [PubMed: 20633948].
  • 12. Hormati A, Hajiani E, Alavinejad P, Shayesteh AA, Masjedizadeh AR, Hashemi SJ. Evaluation of breast cancer radiotherapy induced liver fibrosis by elastography. J Gastroenterol Hepatol Res. 2014;3(8):1026-209.
  • 13. Hormati A, Shakeri M, Iranikhah A, Afifian M, Sarkeshikian SS. [Non-alcoholic fatty liver disease]. Govaresh. 2019;23(4):203-12. Persian.
  • 14. Iranikhah A, Hormati A, Shakeri M, Aghaali M. [Non-alcoholic fatty liver disease in children]. J Mazandaran Univ Med Sci. 2018;28(165):230-42. Persian.
  • 15. Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B. Adv Ther. 2015;32(8):727-41. doi: 10.1007/s12325-015-0232-2. [PubMed: 26329749]. [PubMed Central: PMC4572721].
  • 16. Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol. 2015;21(43):12421-9. doi: 10.3748/wjg.v21.i43.12421. [PubMed: 26604649]. [PubMed Central: PMC4649125].
  • 17. Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, et al. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed. 2014;26(3):172-6. doi: 10.5455/msm.2014.26.172-176. [PubMed: 25126010]. [PubMed Central: PMC4130668].
  • 18. Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Rev Gastroenterol Hepatol. 2018;12(4):331-9. doi: 10.1080/17474124.2018.1439379. [PubMed: 29431526].
  • 19. Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62(1):18-23. doi: 10.1016/j.jhep.2014.08.013. [PubMed: 25135867]. [PubMed Central: PMC4272642].
  • 20. Chen CI, Kuan CF, Fang YA, Liu SH, Liu JC, Wu LL, et al. Cancer risk in HBV patients with statin and metformin use: A population-based cohort study. Medicine (Baltimore). 2015;94(6). e462. doi: 10.1097/MD.0000000000000462. [PubMed: 25674734]. [PubMed Central: PMC4602747].
  • 21. Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: A systematic review and meta-analysis. Am J Gastroenterol. 2017;112(10):1495-505. doi: 10.1038/ajg.2017.170. [PubMed: 28585556].
  • 22. Price JC, Tien PC. Editorial: Statins and liver disease: Is it time to recommend statins to prevent liver disease progression? Am J Gastroenterol. 2017;112(10):1506-7. doi: 10.1038/ajg.2017.250. [PubMed: 28978973].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments